文献类型：期刊文献

中文题名：黄芪总皂苷对H_(22)荷瘤小鼠肿瘤抑制作用及机制

英文题名：Inhibitive effect of total astragalus saponin on tumor and its mechanism in H_(22)-bearing mice

作者：安方玉[1];刘雪松[1];颜春鲁[1];骆亚莉[1];刘永琦[1,2];史旭锋[3];刘兴吉[3]

第一作者：安方玉

机构：[1]甘肃中医学院甘肃省高校重大疾病分子医学与中医药防治研究省级重点实验室,甘肃兰州730000;[2]敦煌医学与转化省部共建教育部重点实验室;[3]甘肃中医药大学临床学院

第一机构：甘肃中医药大学科研实验中心（甘肃省中医药标准化技术委员会秘书处）

年份：2017

卷号：33

期号：4

起止页码：596

中文期刊名：中国公共卫生

外文期刊名：Chinese Journal of Public Health

收录：CSTPCD;;北大核心:【北大核心2014】；CSCD:【CSCD_E2017_2018】；

基金：2012年甘肃省科技支撑计划(1204FKCA169);甘肃中医药大学中西医结合重点学科基金;甘肃中医药大学学生创新基金

语种：中文

中文关键词：黄芪总皂苷;H22;苛瘤小鼠;肿瘤抑制;免疫功能

外文关键词：total saponin of astragalosides ; H22 tumor-bearing mice; tumor suppression; immune function

摘要：目的探讨黄芪总皂苷对小鼠肝癌H_(22)肿瘤生长及免疫功能影响。方法建立小鼠肝癌H_(22)移植瘤模型,小鼠随机分为对照组、模型组、黄芪总皂苷高、中、低剂量组;称重法检测小鼠抑瘤率、脾脏指数、胸腺指数;噻唑蓝法检测小鼠淋巴细胞增殖能力及T淋巴细胞转化能力,酶联免疫法检测小鼠血清中白细胞介素-2(IL-2)含量。结果与对照组比较,模型组小鼠体重[(24.90±2.82)g]明显减轻,胸腺、脾脏指数[分别为(1.47±0.45)、(3.97±0.05)mg/g]明显下降,淋巴细胞增殖能力(0.10±0.02)及转化能力[(1.08±0.03)%]明显降低,血清IL-2含量[(87.59±28.60)pg/m L]明显下降(P<0.05);与模型组比较,黄芪总皂苷各剂量组小鼠肿瘤生长均明显受到抑制,黄芪总皂苷低、中、高剂量组小鼠胸腺与脾脏指数[分别为(2.18±0.34/)、(2.47±0.54/)、(2.51±0.46/)与(5.42±0.84)、(6.13±0.71)、(6.46±0.85)mg/g]升高,淋巴细胞增殖能力[分别为(0.17±0.01)、(0.18±0.03)、(0.19±0.01)]和T淋巴细胞转化能力[分别为(1.14±0.07)、(1.15±0.06)、(1.20±0.07)%]增强,血清IL-2含量[分别为(117.67±30.28)、(121.80±34.04)、(124.93±37.10)pg/m L]升高。结论黄芪总皂苷可抑制小鼠肝癌H_(22)肿瘤细胞的增殖,其机制可能与增强机体的免疫功能有关。
Objective To investigate the effect of different concentration of total astragalus saponin on the growth of tumor ceils and immune function in H22-bearing mice. Methods The H22 liver tumor model was established and the H22-bearing mice were randomly divided into a tumor beating model group,low-, medium-, and high-dose total astragalus saponin treatment groups;a control group was also set. At the end of 10 day＇s treatment, tumor inhibition ratio, spleen index, and thymus index of all the mice were determined with weighing method;multiplication capacity of lymphocytes and the transformation ability of T lymphocytes were tested with 3-（4,5-dimethylthiazol-2-yl）-2,5-diphenyltetrazolium bro- mide （MTT） assay;meanwhile, interleukin-2 （IL-2） content was detected with enzyme-linked immunosorbent assay （ELISA）. Results Compared with those in the control group, the body weight （24. 90±2. 82 g）, thymus index （ 1.47±0. 45 mg/g） ,and spleen index （3.97±0.05 mg/g） decreased significantly in the model group （P 〈0.05 for all） ; the lymphocyte multiplication capacity （0. 10±0. 02） and the T lymphocyte transformation ability （ 1.08±0. 03 ） declined obviously in the model group （both P 〈0. 01 ） ;the IL-2 content （87.59 ＋28.60 pg/ml） was significantly down-regulated in the model group （P 〈 0. 01 ）. Compared to that in the model group, the growth of tumor in total astragalus saponin treatment groups was obvious inhibited （P 〈 0. 01 ）. For the mice of low-, medium-, and high-dose total astragalus saponin treatment groups, the thymus index （ 2. 18 ±0. 34,2.47±0. 54, and 2. 51±0. 46 mg/g）, the spleen index （ 1.14±0. 07,6. 13±0. 71, and 6.46±0. 85 mg/g ）, the capacity of lymphocyte multiplication （ 0. 17±0.01,0. 18±0. 03, and 0. 19±0. 01 ）, the lymphocyte transformation （5.42±0. 84,1. 15±0. 06, and 1.20±0. 07 ）, and the content of IL-2 （ 117.67±30. 28,121.80±34. 04,and 124. 93±37. 10 pg/ml） were all higher than those of the model group. Conclusion The total astragalus saponin could inhibit the proliferation of tumor cells in H22-bearing mice and the mechanism of the inhibitive effect may be related to increased immune function.